Skip to main content
. 2022 May 10;126:64–69. doi: 10.1016/j.jhin.2022.05.001

Table I.

Characteristics of clinical carbapenemase-producing Enterobacterales (CPE) isolates from COVID-19 ICU

Characteristic Patient no.
1 2 3 4 5 6 7
Whole-genome sequencing ID 21-004-0626 21-004-0642 MI21812817 21-004-0654 21-004-0652 21-004-0651 21-004-0653
Organism Klebsiella pneumoniae Klebsiella pneumoniae Klebsiella pneumoniae Klebsiella pneumoniae Klebsiella pneumoniae Klebsiella pneumoniae Klebsiella pneumoniae
Resistance genotype OXA-48 OXA-48 OXA-48 OXA-48 OXA-48 OXA-48 OXA-48
CTX-M-15 CTX-M-15 CTX-M-15 CTX-M-15 CTX-M-15 CTX-M-15 CTX-M-15
aac (3)-IId aac (3)-IId aac (3)-IId aac (3)-IId aac (3)-IId aac (3)-IId aac (3)-IId
Plasmid replicon type IncL IncL IncL IncL IncL IncL IncL
Porin mutations ompK35/ompK36 ompK35/ompK36 ompK35/ompK36 ompK35/ompK36 ompK35/ompK36 ompK35/ompK36 ompK35/ompK36
Meropenem MIC (mg/L) >32 >32 >32 >32 >32 >32 >32
Sample type Sputum Sputum Screen Screen Screen Screen Screen
Days from ICU admission to CPE detection 24 5 13 6 9 10 5
Prior MRO screen Negative Negative Nil Negative Negative Negative Nil
Bed space common with other CPE patient Y Y Y Y Y Y Y
Bed space common with positive environmental screen N Y N N N N N
Mechanically ventilated Y Y Y Y Y Y Y
Antibiotics received prior to CPE isolation Piperacillin/tazobactam, flucloxacillin, cefepime Piperacillin/tazobactam, clindamycin, vancomycin, metronidazole Piperacillin/tazobactam, amoxicillin/clavulanate, vancomycin Amoxicillin/clavulanate Amoxicillin/clavulanate, piperacillin/tazobactam, cefepime Ceftriaxone, piperacillin/tazobactam Ceftriaxone, azithromycin

CPE, carbapenemase-producing Enterobacterales; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; MIC, minimum inhibitory concentration; MRO, multidrug-resistant organism; NA, not available; ompK35/ompK36, premature stop codon in the outer membrane porin gene ompK35 and insertion in loop 3 of ompK36.